Inmune Bio (INMB) Income from Continuing Operations (2018 - 2026)
Inmune Bio (INMB) posted Income from Continuing Operations of 6071000.0 for Q1 2026, down 0.86% sequentially from 6019000.0 in Q4 2025, and up 68.51% YoY from 3602828.16 in Q1 2025.
Inmune Bio (INMB) Income from Continuing Operations (2018 - 2026) Analysis & Trends
Inmune Bio has reported Income from Continuing Operations for 9 years, with the latest figure at 6071000.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 68.51% year-over-year to 6071000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 45448000.0 (up 78.11% YoY) and the FY2025 annual result came in at 82093000.0, down 20.15% from the prior year.
- Income from Continuing Operations retreated to 6071000.0 in Q1 2026 per INMB's latest filing, from 6019000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 6019000.0 in Q4 2025 and troughed at 532443000.0 in Q3 2022.
- A 5-year average of 51607294.12 and a median of 9263000.0 in 2023 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2023 and 2024: Income from Continuing Operations soared 97.48% in 2023, then sank 1072.11% in 2024.
- Over 5 years, Income from Continuing Operations stood at 6499000.0 in 2022, then slumped by 42.53% to 9263000.0 in 2023, then declined by 13.31% to 10496000.0 in 2024, then jumped by 42.65% to 6019000.0 in 2025, then slipped by 0.86% to 6071000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 6071000.0, 6019000.0, and 8635000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Inmune Bio | 61.59 Mn | 43.18 Mn | - | -1.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.09 Mn |
| Mar 31, 2026 | -6.07 Mn |
| Dec 31, 2025 | -6.02 Mn |
| Sep 30, 2025 | -8.64 Mn |
| Jun 30, 2025 | -24.72 Mn |
| Mar 31, 2025 | -19.28 Mn |
| Dec 31, 2024 | -10.50 Mn |
| Sep 30, 2024 | -157.29 Mn |
| Jun 30, 2024 | -20.52 Mn |
| Mar 31, 2024 | -34.83 Mn |
| Dec 31, 2023 | -9.26 Mn |
| Sep 30, 2023 | -13.42 Mn |
| Jun 30, 2023 | -7.04 Mn |
| Mar 31, 2023 | -7.04 Mn |
| Dec 31, 2022 | -6.50 Mn |
| Sep 30, 2022 | -532.44 Mn |
| Jun 30, 2022 | -6.85 Mn |
| Mar 31, 2022 | -6.91 Mn |
| Dec 31, 2021 | -9.47 Mn |
| Sep 30, 2021 | -54.19 Mn |